CAS Medical Systems, Inc. Provides Update on FORE-SIGHT Absolute Cerebral Oximeter

Branford, Conn. – February 11, 2009 – CAS Medical Systems, Inc. (NasdaqGM: CASM), a leader in non-invasive monitoring that is vital to patient care, today provided an update on its FORE-SIGHT® Absolute Cerebral Oximeter.

In 2008 the Company achieved several significant milestones with regard to FORE-SIGHT, including:

• The European product introduction with positive sales results
• Becoming the first company to receive FDA 510(k) clearance for the neonatal application of cerebral oximetry
• The commercial launch of the neonatal/infant sensor
• A four-fold increase in the installed base of monitors to a total of 151 at the end of 2008

Andrew E. Kersey, President and CEO of CASMED, states, “We made great strides in 2008 with our FORE-SIGHT Absolute Cerebral Oximeter, increasing market awareness of the benefits of cerebral oximetry as well as the specific advantages offered by FORE-SIGHT.  While the current economic climate creates challenges for all companies, we plan to build on our success to date and remain confident that the importance of cerebral oximetry as a standard of care and the superiority of our absolute measurement technology will provide growth opportunities in 2009.”

Clinically, the volume of evidence supporting the use of the FORE-SIGHT technology continues to increase. Studies, such as those published recently in the Journal of Perinatology, Neonatal Intensive Care, British Journal of Anesthesia and Seminars in Cardiothoracic and Vascular Anesthesia demonstrate the value of cerebral oximetry monitoring to maintenance of cerebral oxygenation levels during procedures such as extracorporeal membrane oxygenation (ECMO) therapy and to indicate the effectiveness of chest compressions during CPR.  CASMED expects publication of additional studies and abstracts in the coming months.

Throughout 2009, CASMED will continue to invest to develop the cerebral oximetry market. The Company recently added a new director of clinical affairs and a re-aligned the FORE-SIGHT sales team in both the neonatal/infant and adult arenas.  CASMED currently has a total of 12 sales and clinical specialists focused exclusively on FORE-SIGHT, supplemented by key U.S. manufacturer’s representative groups and international distributors.

The Company’s 2009 goals include expanding its contacts with thought leaders and teaching institutions around the world, as well as expanding its distribution in Europe.  In addition, CASMED expects to launch new product enhancements to FORE-SIGHT and to receive additional FDA 510(k) clearances to expand its product portfolio.

The FORE-SIGHT Absolute Cerebral Oximeter will be featured at a number of scientific meetings this quarter.  In addition to the Society of Thoracic Surgeons last month, attendance is planned in February at the German Society for Thoracic Surgery, the Conference on Brain Monitoring and Neuroprotection in the Newborn, and the CNMC Symposium on ECMO and Advanced Therapies for Respiratory Failure.  March shows include the American Society of Extracorporeal Technology, the Society of Cardiovascular Anesthesiologists Update on Cardiopulmonary Bypass, and the Society for Pediatric Anesthesia.

About CASMED^® - Monitoring What’s Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring.  The Company’s FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults.  This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.

The Company’s product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs and cardio-respiratory monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care.  CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.

For further information regarding CAS Medical Systems, Inc., visit the Company’s website at www.casmed.com.

Company Contacts
CAS Medical Systems, Inc.
Susan Carron
Director of Corporate Communications
203-488-6056
ir@casmed.com

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, commercialization and technological difficulties, the impact of actions and events involving key customers and vendors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2007 and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.